
News|Articles|October 1, 2012
Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis
Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars in 2025: A year of firsts
2
What IRA drug prices will mean for PBMs, health plans and patients
3
Looking ahead: What the MHE 2025 State of the Industry survey tells us about 2026
4
FDA approves first postmenopausal libido treatment, Addyi
5






















































